



News Updates: March 21, 2014

Patents/Compulsory Licensing/Intellectual Property

Publication: The Economic Times

Edition: National

Date: March 21, 2014

Headline: [US leads the world in use of compulsory licenses: KEI](#)

Synopsis: While the US Government and strong American pharma sector have been up in arms against India for issuing compulsory licence in the sector, an eminent global non-governmental organisation has said that it is the United States which leads the world in use of compulsory licenses. The United States "is leading the world in the use of compulsory licenses, and is hypocritical in voicing indignance when developing countries issue compulsory licenses for essential drugs," Washington-based Knowledge Ecology International (KEI), with its offices in Geneva, has alleged.

Similar reports in-

The Financial Express- [US leads the world in use of compulsory licenses: KEI](#)

The Financial Chronicle- [US leads in use of compulsory licenses: KEI](#) (link unavailable, scan attached)

FDA

Publication: The Hindustan Times

Edition: National

Date: March 21, 2014

Headline: [Wockhardt gets FDA notice for violating waste disposal norms](#) (link unavailable, scan attached)

Synopsis: The state Food and Drug Administration (FDA) has served a showcause notice to Wockhardt Limited (WL), a multinational pharmaceutical and biotechnology company for not adhering to standard operating procedure (SOP) for waste disposal facilities and Good Manufacturing Practices (GMP).

Similar report in-

Daily News & Analysis- [Pharma firm gets FDA notice](#)

Clinical Trials

Publication: The Financial Chronicle

Edition: Delhi

Date: March 21, 2014

Headline: [GSK cancer vaccine fails second test](#) (link unavailable, scan attached)

Synopsis: An experimental cancer vaccine from GlaxoSmithKline has failed in a second test - this time against lung cancer - but the British company said it still hoped to identify a sub-group of patients in which it would work. Thursday's news that the MAGE-A3 therapeutic vaccine did not help patients with non-small cell lung cancer in a late-stage study is a further blow to the high-risk, high-reward project after a similar setback in melanoma in September.

Similar reports in-

Reuters- [GSK cancer vaccine fails again but testing continues](#)

Pharmabiz- [GSK's phase III trial of MAGE-A3 cancer immunotherapeutic in NSCLC patients fails to meet endpoint](#)

Drug Quality

Publication: The Economic Times

Edition: National

Date: March 21, 2014

Headline: [Indian manufacturing issues suggest generic drugs shake-out: Novartis](#)

Synopsis: Recent manufacturing problems in India suggest some makers of generic drugs will struggle to compete in the face of a rising quality bar, pointing to a likely a shake-out in the low-cost sector, according to Novartis. Chief Executive Joe Jimenez said the Swiss group's Sandoz unit - a world leader in making cheap off-patent medicines - was well placed to thrive in an era of tougher standards. Others, however, would not be able to upgrade and stay competitive.

Similar reports in-

Business Standard- [Quality woes point to generic drugs shake-out: Novartis](#)

Reuters- [Quality woes point to generic drugs shake-out: Novartis](#)

Drug Pricing

Publication: Business Standard

Edition: National

Date: March 21, 2014

Headline: [Consumers may have to pay more for insulin](#)

Synopsis: Popular domestic brands of insulin analog Glargine (the chemical name) are in short supply for the past few months, forcing patients to switch to expensive imported alternatives, it is learnt. According to sources, Wockhardt, which sells the product under its brand Glaritus, could not manufacture the insulin for at least six months following bulk drug supply disruptions from China.

Website: Pharmabiz

Edition: National

Date: March 21, 2014

Headline: [Maha FDA asks NPPA to take strict action against GSK for overpricing Crocin products](#)

Synopsis: Close on the heels of its stop sale action against Crocin Advance, Crocin Suspension and Crocin Drops manufactured by pharma major GlaxoSmithKline (GSK) for overcharging, the Maharashtra Food and Drug Administration (FDA) has asked the national drug regulator NPPA to take appropriate legal action against the company for violation of new Drug Price Control Order (DPCO).

General Industry

Publication: The Economic Times

Edition: National

Date: March 21, 2014

Headline: ['Bulk drug industry needs to be strengthened'](#)

Synopsis: There is a need to look at strengthening development of the bulk drug industry in India as the country offers tremendous potential in research and development, a senior government official said here today. "There is a need to look at strengthening the development of the bulk drug industry in India. There are various challenges being faced by the Indian pharmaceutical industry," Department of Pharmaceuticals, Secretary Aradhana Johri, said while addressing the 5th India Pharma Summit organised by FICCI here.

Website: Pharmabiz

Edition: National

Date: March 21, 2014

Headline: [Indian pharma industry to make 27% growth by 2016, says Deloitte report](#)

Synopsis: India's pharmaceutical sales, worth 22.6 billion dollar in 2012, is expected to register 27 per cent growth to reach 27 billion dollar by 2016, according to the Deloitte 2014 Global Life Sciences Outlook report. "India's pharmaceutical sales were \$22.6 billion in 2012. They are expected to rise to \$23.6 billion in 2013 and reach \$27.0 billion in 2016. As a per cent of health care expenditures, pharmaceutical sales were 22.6 per cent in 2012; they are expected to reach 23.6 per cent in 2013 and 27 per cent by 2016," says the report.